This is the authors' abstract. We don't add key points for this paper.
RESEARCH LETTER Ruxolitinib for refractory chronic GVHD 1 As a second -line treatment, the patients received tacrolimus or mycophenolate mofetil (MMF; in the case of contradictions to the use of calcineurin inhibitors).The following agents were used as subsequent treatments: methotrexate, imatinib, and ECP.Two patients diagnosed with bronchiolitis obliterans received FAM (fluticasone, azithromycin, and montelukast).The study was carried out in accordance with the principles of the Declaration of Helsinki.All patients gave their written informed consent to participate. Diagnosis of steroid -resistant chronic graft -versus--host diseaseThe 2014 National Institutes of Health (NIH) Grading System was applied for the diagnosis of cGVHD. 4,5GVHD severity was assessed at the start of the RUX treatment.Steroid refractoriness was defined as: 1) progression of cGVHD while on MP at a dose of 1 mg/kg/day or higher for 1 to 2 weeks; 2) stable cGVHD while on MP at a dose of 0.5 mg/kg/day or higher for at least 4 weeks. 6Ruxolitinib dosing and definitions of response RUX was initiated orally at 5 mg twice daily, and the dose was subsequently increased to 10 mg twice daily in 6 patients.Doses of other immunosuppressants were gradually diminished while the patients received RUX.Assessment of response to the RUX therapy was performed following the NIH criteria. 4 Complete remission (CR) was defined as total resolution of cGVHD manifestations; partial remission (PR) was considered as improvement in the score as compared with the baseline, reflecting a real clinical benefit.Other responses, that is, stable disease, progression, or mixed responses were considered as treatment failure.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Spałek et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: